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tension and glaucoma. Validation is currently underway to
examine the psychometric properties of the EDSQ questionnaire.
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OBJECTIVES: In the absence of comparative trials, to perform
a direct and indirect meta-analysis of the efﬁcacy and tolerabil-
ity of pramipexole (PPX) and ropinirole (RPR), both widely
approved treatments in RLS. METHODS: Clinical trials were
identiﬁed from a systematic search and clinical reports. Study
inclusion criteria: studies in idiopathic RLS, randomized, double-
blind, placebo-controlled, parallel group, primary endpoint:
International Restless Legs Rating Scale (IRLS). Pre-speciﬁed
analyses were: ﬁxed and random-effects models for direct com-
parisons and a Bayesian approach for the indirect comparison,
PPX vs. RPR, using placebo as the common comparator. Non-
inferiority of PPX vs. RPR was tested ﬁrst and then superiority.
Efﬁcacy criteria were: IRLS mean change from baseline and per-
centage of responders on the Clinical Global Impressions-
Improvement scale (CGI-I). Tolerability criteria were: incidence
of withdrawal and incidence of AEs occurring in >5% of
patients. RESULTS: Two trials were eligible for inclusion for
PPX (n = 689) and three for RPR (n = 931). The direct meta-
analysis, using random-effects model, conﬁrmed superior efﬁ-
cacy for both treatments vs. placebo measured as change on the
IRLS (PPX: −5.5; 95% CI: −7.7; −3.2; RPR: −3.2; 95% CI: −4.3;
−2.1) and for the CGI-I (PPX: OR = 3.0; 95% CI: 2.1; 4.3; RPR:
OR = 2.0; 95% CI: 1.5; 2.6). Compared to placebo the incidence
of nausea was signiﬁcantly higher for PPX (p < 0.01), whereas
dizziness, nausea, somnolence and vomiting were signiﬁcantly
higher for RPR (all p < 0.01). The Bayesian indirect comparison
showed a superior reduction on the IRLS for PPX vs. RPR of
”C2.3 points, and had an OR = 1.5 for the CGI-I responders.
The superior reduction on the IRLS, the higher CGI-I responder
rate and the reduced incidence of nausea and vomiting for PPX
vs. RPR were observed with a probability of ••97%. CON-
CLUSIONS: Results of the indirect meta-analysis were in favour
of PPX vs. RPR for IRLS and CGI-I and for the tolerability out-
comes nausea and vomiting.
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OBJECTIVES: With about 33 million children affected world-
wide, epilepsy is a common neurological disorder creating sig-
niﬁcant socio-economic costs. This study aims to estimate the
additional costs or savings generated by the introduction of lev-
etiracetam for refractory partial onset seizure (POS) in paediatric
patients in the UK. METHODS: A budget impact model was
built from the UK NHS perspective, for a 5-year time period.
Levetiracetam adjunctive therapy was compared with standard
treatments (ST): lamotrigine, oxcarbazepine, valproic acid, car-
bamazepine and topiramate. Epidemiological paediatric popula-
tion data such as prevalence of refractory POS cases were
obtained from the published literature and combined with UK
population projections for 2005 from ofﬁcial statistics sources.
Patients on levetiracetam were divided into three groups: new,
existing and withdrawing patients to reﬂect the progressive
adoption of the treatment. The cost of medications and hospi-
talizations were included and expressed in 2005 UK£. RESULTS:
During the ﬁrst year, the number of paediatric patients with
refractory POS was estimated to be 7205. The annual cost per
patient for current ST was £1593, resulting in a total budget of
£11.5 million. Within the next ﬁve years, the number of paedi-
atric patients will increase to 7267, resulting in a total budget of
£11.6 million. Adding levetiracetam to ST increased the yearly
drug costs by £1089 per patient. This additional cost was partly
offset by lower hospitalization costs (£332 and £815 per patient
for levetiracetam and ST respectively). Introducing levetiracetam
resulted in a budget increase to £11.7 million (+1.8% compared
to current budget) during the ﬁrst year and £12.1 million
(+4.7%) over the next ﬁve years. CONCLUSION: Levetiracetam
as adjunctive therapy in paediatric patients with refractory POS
is predicted to result in a modest increase in UK NHS paediatric
epilepsy expenditure of 4.7% within a 5-year time period.
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OBJECTIVE: To assess the cost-effectiveness of add-on therapy
drugs within the formulary of the Mexican Institute of Social
Security for partial refractory epilepsy. METHODS: Cost-
effectiveness study that used costs information from a retro-
spective cohort of a multicentric study. Efﬁcacy (>50% seizure
reduction) and adverse events of oxcarbazepine, topiramate, lev-
etiracetam and lamotrigine were obtained from a meta-analysis.
Experts suggested excluding vigabatrin from the analysis, and
gabapentin was also eliminated because IMSS formulary recom-
mends its use only for neuropathic pain. Study perspective was
institutional with 1 year time horizon, and no discount rate was
used. Costs were estimated from ﬁnancial information from
IMSS, and are reported in US 2006 dollars. A decision tree with
a Bayesian approach included efﬁcacy and adverse events. Mean
cost-effectiveness and incremental ratios, net health beneﬁts and
net economic beneﬁts were calculated. ICER conﬁdence interval
was estimated with ellipse method. Sensitivity analysis included
threshold, scenarios, one-way and probabilistic Monte Carlo
simulation. RESULTS: Levetiracetam had the lowest mean cost-
effectiveness ratio, $6238. Incremental analysis showed that top-
iramate was dominated by levetiracetam, while the ICER for
lamotrigine and oxcarbazepine was $1938 and $2156 compared
with not providing add-on therapy. Acceptability curves showed
that lamotrigine was the most cost-effective option with a WTP
between $955 and $1476. Levetiracetam was the most 
cost-effective option when WTP was above $1476, and the com-
ponents analysis conﬁrmed this result. CONCLUSIONS: Leve-
tiracetam was the alternative with lowest cost per controlled
patient and provided the largest health beneﬁt compared with
using standard therapy alone (not add-on). Topiramate was
dominated by levetiracetam. Standard therapy was the cheapest
alternative; however, due to its low effectiveness, it had more
